ENDEAVOR Stent Trial Shows Positive Results

William Wijns, the co-principal investigator of the Endeavor II pivotal clinical trial and co-director of the Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium, presented positive results of the Endeavor II trial at the American College of Cardiology 54th Annual Scientific Session.

The Endeavor II study demonstrated clinically and statistically significant improvement in all of the study's endpoints, including a 47 percent reduction in the primary endpoint of target vessel failure. The final Endeavor II clinical data showed impressive reduction in repeat procedures and vessel renarrowing. The trial enrolled 1,197 patients at 72 facilities in 17 countries, making it the first and largest drug-eluting stent trial comparing a drug-eluting stent to a bare metal stent ever performed outside the U.S.

The Endeavor II Clinical Trial, sponsored by Medtronic, was a randomized, double-blind, pivotal trial designed to evaluate the safety and efficacy of Medtronic's Endeavor drug-eluting coronary stent compared to Medtronic's Driver cobalt alloy coronary stent in patients with coronary artery disease.